REMARKS

Currently claims 1-6, 8, and 10-11 are pending. Please cancel claims 7 and 9.

Applicants amend the claims to remove unintentional duplication, place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. No new matter is added by these amendments.

Applicants amend the specification for purposes of adding the priority information.

The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

John L. Lemanowicz

Attorney for Applicant Registration No. 37,380

Date: 6/6/03 GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone:

919-483-8247

Facsimile: 919-483-7988